Moreover, the inhibition of GSK3β, SIRT1 activity, and proteotoxicity could concomitantly serve as a viable therapeutic approach to enhance NAFLD/NASH treatments. This evidence concerns the gene GSK3B and metabolic dysfunction-associated steatohepatitis.